Home › NDC Lookup › J-codes › J9326
J9326

J9326 – Telisotuzumab vedotin-tllv · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 2 NDCs crosswalked per 1 MG $146.060/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9326 summary

J9326 is a HCPCS Level II J-code used to bill Telisotuzumab vedotin-tllv, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9326: Emrelis

Code J9326 Billing unit 1 MG Payment limit $146.060/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9326
DescriptorTelisotuzumab vedotin-tllv
Billing unit1 MG
Payment limit / unit$146.060
Est. ASP / unit$137.792 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$146.060
Est. ASP / unit
$137.792 est.
Est. after 2% sequester
$143.139
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9326 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9326 WITH EST. MEDICARE PAY

2 NDCs map to J9326. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($146.060/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00074-1044-01 EMRELIS Telisotuzumab Vedotin 20 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION AbbVie 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-1044... 20 mg/mL 20 $2,921.20 — ● Active CMS ASP
00074-1055-01 EMRELIS Telisotuzumab Vedotin 100 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION AbbVie 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-1055... 100 mg/mL 100 $14,606.00 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Total Part B spend
$7.18M
Claims
358
Beneficiaries
115
Spend / beneficiary
$62,437.69
Spend / claim
$20,056.80
Where J9326 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #207 of 824
#202 VPRIV J3385 $7.61M #203 HUMATE-P J7187 $7.45M #204 HERCEPTIN HYLECTA J9356 $7.41M #205 ZYNLONTA J9359 $7.38M #206 TRIESENCE J3300 $7.37M #207 EMRELIS J9326 $7.18M #208 PEMFEXY J9304 $7.15M #209 JELMYTO J9281 $7.14M #210 SEVENFACT J7212 $7.11M #211 FYLNETRA Q5130 $6.83M #212 YONDELIS J9352 $6.7M
Total claims — #489 of 824
#484 CYCLOPHOSPHAMIDE(J90... J9076 372 #485 PROVOCHOLINE J7674 371 #486 SIMPLIMAX, PER SQ CM... Q4341 365 #487 NALBUPHINE HCL J2300 362 #488 DIAZEPAM J3360 361 #489 EMRELIS J9326 358 #490 BLEOMYCIN SULFATE J9040 349 #491 THERAMEND, PER SQ CM... Q4342 346 #492 PREVNAR 13 90670 342 #493 SUSVIMO J2779 342 #494 BIO-CONNEKT PER SQUA... Q4161 334

Full breakdown by period (1)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $7.18M 115 358 $62,437.69 $20,056.80
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9326 billing FAQ

What is HCPCS code J9326?
J9326 is a HCPCS Level II J-code used to bill Telisotuzumab vedotin-tllv under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9326?
One unit of J9326 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J9326 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9326?
The Medicare Part B payment limit is $146.060 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $143.139 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9326?
2 NDCs currently map to J9326 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9326 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.